Galectin Therapeutics(NASDAQ) GALT

Current Price$3.90

Market Cap$263.43M

Since IPO (2002)-67%

5 Year+42%

1 Year+43%

1 Month+42%

Galectin Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 4.00	2026-07-20

Galectin Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-13.04%	USD 4.60	2026-07-13
1 month	+41.59%	USD 2.83	2026-06-18
3 month	+75.44%	USD 2.28	2026-04-21
Year to date	-3.85%	USD 4.16	2025-12-31
1 year	+42.86%	USD 2.80	2025-07-18
3 year	+145.4%	USD 1.63	2023-07-21
5 year	+41.84%	USD 2.82	2021-07-21
Since inception	-66.67%	USD 12.00	2002-09-04

Galectin Therapeutics Financials at a Glance

Market Cap

$263.43M

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.25M

EPS (TTM)

-$0.41

P/E Ratio

-9.76

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$3.90

Volume

224,812.696

Open

$4.01

Price

$3.90

Volume

224,812.696

Open

$4.01

Previous Close

$4.00

Daily Range

$3.86 - $4.15

52-Week Range

$2.03 - $7.13

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$3.90

Volume

224,812.696

Open

$4.01

Previous Close

$4.00

Daily Range

$3.86 - $4.15

52-Week Range

$2.03 - $7.13

Estimated Earnings Date

Aug 13, 2026

GALT News

Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks

Sean WilliamsMar 25, 2014

Why Galectin Therapeutics, Inc. Shares Soared

Sean WilliamsMar 25, 2014

Page 1

GALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galectin Therapeutics

Galectin develops medicines for people with liver disease and cancer. Its main drug aims to slow liver damage in patients with fatty liver disease. The company’s research targets conditions with few current treatment options.

What’s in the Medicine Cabinet?

Belapectin (GR-MD-02): Lead drug in late-stage trials for liver fibrosis in fatty liver disease; also studied for cancer and other fibrotic diseases. Represents 0% of revenue as the company is pre-commercial.
GM-CT-01: Early-stage drug for heart and blood vessel scarring; not yet in human trials. 0% of revenue.
Small Molecule Inhibitors: Oral drugs in development for blocking galectin-3, a protein linked to disease progression. 0% of revenue.

Growth Moves: Not Just a Science Project

Formed joint venture Galectin Sciences, LLC with SBH Sciences to develop new oral drugs (year not specified).
Launched NAVIGATE Phase 2b/3 trial for belapectin in NASH cirrhosis, with protocol filed in 2020 and enrollment completed in early 2023.
Secured $10 million line of credit from chairman in July 2025 to support operations.
Filed for FDA clearance for a new cancer trial in 2022.

Why Galectin Is a Bit Different

Galectin focuses on diseases with few treatment options, using a unique approach that targets the galectin-3 protein. Its clinical trial design adapts to regulatory feedback, aiming for meaningful patient outcomes. The company’s small size allows for focused research and quick decision-making.

Five Things You Need to Know

No revenue reported for 2023, 2024, or 2025; all products are in development.
Net loss was $17.2 million for the first half of 2025, a 28.1% improvement from 2024.
Research and development expenses fell 45% year-over-year to $9.7 million in H1 2025.
Cash and equivalents were $13.8 million as of June 30, 2025, down from $15.1 million at year-end 2024.

Bottom Line

Galectin remains a research-focused company with no product sales and ongoing clinical trials. Its future depends on advancing its drug candidates and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Joel Lewis, CPA

Website

www.galectintherapeutics.com

Headquarters

Norcross, GA 30071, US

GALT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

21.05%

Return on Capital

-265.60%

Return on Assets

-166.58%

Earnings Yield

-10.25%

Dividend Yield

0.00%

Payout Ratio

-0.23%

Stock Overview

Market Cap

$263.43M

Shares Outstanding

65.86M

Volume

224.81K

Avg. Volume

635.80K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$16.27M

EBITDA

-$18.62M

Operating Cash Flow

-$20.05M

Capital Expenditure

$0.00

Free Cash Flow

-$20.05M

Cash & ST Invst.

$14.11M

Total Debt

$135.72M

Galectin Therapeutics Performance Analysis

Galectin Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Galectin Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Galectin Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.65	24.8%
2023	2023-12-31	USD -0.74	13.8%
2024	2024-12-31	USD -0.76	1.7%
2025	2025-12-31	USD -0.48	-36.0%

Galectin Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	20.0%
Q3	2025-09-30	-8.3%
Q4	2025-12-31	38.5%
Q1	2026-03-31	3.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$263.43M

N/A

Market Cap/Employee

$29.27M

N/A

Employees

N/A

Net Income

-$5.05M

+47.6%

EBITDA

-$3.05M

+61.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$14.11M

+89.9%

Total Debt

$135.72M

+25.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$135.71M

+1155.1%

Short Term Debt

$6.00K

-100.0%

Return on Assets

-1.67%

N/A

Return on Invested Capital

-1.92%

N/A

Free Cash Flow

-$3.87M

+49.7%

Operating Cash Flow

-$3.87M

+49.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ALTAltimmune, Inc.

ALTAltimmune, Inc.$2.80-0.53%

QSIQuantum-Si incorporated

QSIQuantum-Si incorporated$0.84+2.69%

RCKTRocket Pharmaceuticals, Inc.

RCKTRocket Pharmaceuticals, Inc.$3.37-1.90%

DMACDiaMedica Therapeutics Inc.

DMACDiaMedica Therapeutics Inc.$7.08+1.00%

ENGNenGene Holdings Inc.

ENGNenGene Holdings Inc.$1.91+2.14%

AURAAura Biosciences, Inc.

AURAAura Biosciences, Inc.$7.02+2.86%

IMABI-Mab

IMABI-Mab$2.88-0.69%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ONDSOndas

ONDSOndas$7.59+0.10%

NOKNokia

NOKNokia$10.62+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.19+0.00%

HLHecla Mining

HLHecla Mining$15.15+0.06%

UTZUtz Brands

UTZUtz Brands$14.07+0.89%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$34.72+0.23%

FFord Motor Company

FFord Motor Company$14.27+0.02%

Questions About GALT

What is the current price of Galectin Therapeutics?

Galectin Therapeutics is trading at $3.90 per share.

What is the 52-week range for Galectin Therapeutics?

Over the past 52 weeks, Galectin Therapeutics has traded between $2.03 and $7.13.

How much debt does Galectin Therapeutics have?

As of the most recent reporting period, Galectin Therapeutics reported total debt of $135.72M.

How much cash does Galectin Therapeutics have on hand?

Galectin Therapeutics reported $14.11M in cash and cash equivalents in its most recent financial results.

What is Galectin Therapeutics’s dividend yield?

Galectin Therapeutics does not currently have a dividend yield.

Galectin Therapeutics(NASDAQ) GALT

Galectin Therapeutics Financials at a Glance

GALT News

Galectin Beats Q2 Loss Estimates

3 Stocks That Could Double Your Money

Why Galectin Therapeutics Stock Bolted Higher Today

2 Clinical-Stage Biotech Stocks That Could Soar Next Week

3 NASH Stocks That Could Soar in the Second Half of 2018

Why Galectin Therapeutics Inc. Shares Jumped

Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks

Why Galectin Therapeutics, Inc. Shares Soared

GALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Galectin Therapeutics

What’s in the Medicine Cabinet?

Growth Moves: Not Just a Science Project

Why Galectin Is a Bit Different

Five Things You Need to Know

Bottom Line

GALT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Galectin Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GALT

What is the current price of Galectin Therapeutics?

What is the 52-week range for Galectin Therapeutics?

How much debt does Galectin Therapeutics have?

How much cash does Galectin Therapeutics have on hand?

What is Galectin Therapeutics’s dividend yield?

Premium Investing Services